Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combination therapy for obesity
John Wilding
Journal of Psychopharmacology (2017) Vol. 31, Iss. 11, pp. 1503-1508
Closed Access | Times Cited: 36

Showing 1-25 of 36 citing articles:

Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Young Jin Tak, Sang Yeoup Lee
Current Obesity Reports (2021) Vol. 10, Iss. 1, pp. 14-30
Open Access | Times Cited: 261
Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity
Maria J. Pereira, Jan W. Eriksson
Drugs (2019) Vol. 79, Iss. 3, pp. 219-230
Open Access | Times Cited: 255
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial
Lone B Enebo, Kasper K. Berthelsen, Martin Kankam, et al.
The Lancet (2021) Vol. 397, Iss. 10286, pp. 1736-1748
Closed Access | Times Cited: 218
Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review
Young Jin Tak, Sang Yeoup Lee
The World Journal of Men s Health (2020) Vol. 39, Iss. 2, pp. 208-208
Open Access | Times Cited: 129
Flavonoids as antiobesity agents: A review
Ana T. Rufino, Vera Marisa Costa, Félix Carvalho, et al.
Medicinal Research Reviews (2020) Vol. 41, Iss. 1, pp. 556-585
Closed Access | Times Cited: 127
Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022
Harold Bays, Angela Fitch, Sandra Christensen, et al.
Obesity Pillars (2022) Vol. 2, pp. 100018-100018
Open Access | Times Cited: 47
The future of human malnutrition: rebalancing agency for better nutritional health
Jonathan C. K. Wells, Akanksha A. Marphatia, Gabriel S. Amable, et al.
Globalization and Health (2021) Vol. 17, Iss. 1
Open Access | Times Cited: 50
Pharmacotherapy before and after bariatric surgery
Khaled Alabduljabbar, Carel W. le Roux
Metabolism (2023) Vol. 148, pp. 155692-155692
Closed Access | Times Cited: 16
The interplay of leptin and the peripheral endocannabinoid system in energy homeostasis and obesity; modulation by linoleic acid and exercise
Quratul Ain, Melpomeni Malamouli, Deanne H. Hryciw
Advanced Exercise and Health Science (2025)
Open Access
Revolutionizing Fixed-Dose Combinations with Long-Acting Microsphere
Zhenhua Hu, Xiao Xiao, Guiyun Zhang, et al.
European Journal of Pharmaceutical Sciences (2025), pp. 107032-107032
Open Access
Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)
Sanjay Kalra, Saptarshi Bhattacharya, Nitin Kapoor
Diabetes Therapy (2021) Vol. 12, Iss. 8, pp. 2133-2147
Open Access | Times Cited: 28
Compound combinations targeting longevity: Challenges and perspectives
Olga Y. Rybina, Alexander V. Symonenko, E. G. Pasyukova
Ageing Research Reviews (2023) Vol. 85, pp. 101851-101851
Closed Access | Times Cited: 10
Sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) plus glucagon‐like peptide type 1 receptor combination is more effective than SGLT2i plus dipeptidyl peptidase‐4 inhibitor combination in treating obese mice metabolic dysfunction‐associated steatotic liver disease (MASLD)
Pedro H. Reis‐Barbosa, Carlos Alberto Mandarim‐de‐Lacerda
Fundamental and Clinical Pharmacology (2024) Vol. 38, Iss. 6, pp. 1059-1068
Closed Access | Times Cited: 3
A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss
Maria J. Pereira, Per Lundkvist, Prasad G. Kamble, et al.
Diabetes Therapy (2018) Vol. 9, Iss. 4, pp. 1511-1532
Open Access | Times Cited: 27
Common Polymorphisms of CYP2B6 Influence Stereoselective Bupropion Disposition
Evan D. Kharasch, Amanda Crafford
Clinical Pharmacology & Therapeutics (2018) Vol. 105, Iss. 1, pp. 142-152
Open Access | Times Cited: 20
Neuropeptide receptors as potential pharmacological targets for obesity
Beatriz T. Meneguetti, Marlon H. Cardoso, Camila Fontoura Acosta Ribeiro, et al.
Pharmacology & Therapeutics (2018) Vol. 196, pp. 59-78
Closed Access | Times Cited: 20
Stereoselective Bupropion Hydroxylation by Cytochrome P450 CYP2B6 and Cytochrome P450 Oxidoreductase Genetic Variants
Pan‐Fen Wang, Alicia Neiner, Evan D. Kharasch
Drug Metabolism and Disposition (2020) Vol. 48, Iss. 6, pp. 438-445
Open Access | Times Cited: 15
Intestinal sodium/glucose cotransporter 3 expression is epithelial and downregulated in obesity
Matúš Soták, Anna Casselbrant, Eva Rath, et al.
Life Sciences (2020) Vol. 267, pp. 118974-118974
Open Access | Times Cited: 15
The controversial role of glucose in the diabetic kidney
Rui Fernandes
Porto Biomedical Journal (2021) Vol. 6, Iss. 1, pp. e113-e113
Open Access | Times Cited: 12
Induced expression of AMOT reverses adriamycin resistance in breast cancer cells
Haige Zhang, Yingyi Wang, Ya Gao, et al.
Cell Biology International (2024) Vol. 48, Iss. 9, pp. 1301-1312
Closed Access | Times Cited: 1
Improved metabolic efficacy of a dual amylin and calcitonin receptor agonist when combined with semaglutide or empagliflozin
Simone Anna Melander, Anna Katri, M.A. Karsdal, et al.
European Journal of Pharmacology (2022) Vol. 938, pp. 175397-175397
Closed Access | Times Cited: 7
Potential roles of lncRNA MALAT1-miRNA interactions in ocular diseases
Ava Nasrolahi, Fatemeh Khojasteh Pour, Abdolah Mousavi Salehi, et al.
Journal of Cell Communication and Signaling (2023) Vol. 17, Iss. 4, pp. 1203-1217
Open Access | Times Cited: 3
Artesunate combined with verteporfin inhibits uveal melanoma by regulation of the MALAT1/yes‑associated protein signaling pathway
Xudong Jiu, Yang Liu, Jin Wen
Oncology Letters (2021) Vol. 22, Iss. 2
Open Access | Times Cited: 7
Oral Superabsorbent Hydrogel (Plenity) for Weight Management
Alexa Pass, Damian Bialonczyk, Elaine Chiquette, et al.
Annals of Pharmacotherapy (2020) Vol. 55, Iss. 9, pp. 1146-1152
Closed Access | Times Cited: 7
Inkretinbasierte Ko- und Triagonisten
Alexandra Harger, Kerstin Stemmer, M. Tschöp, et al.
Der Internist (2019) Vol. 60, Iss. 9, pp. 895-902
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top